Britannia Life Sciences Inc.
BLAB
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -38.44% | -64.39% | 483.03% | 657.64% | 1,199.54% |
| Total Depreciation and Amortization | -22.78% | -21.25% | 2.76% | -38.08% | -61.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 73.79% | 84.21% | -735.81% | -2,607.64% | -875.49% |
| Change in Net Operating Assets | -3,622.15% | -408.35% | -171.68% | -119.46% | -105.23% |
| Cash from Operations | 58.44% | 3.25% | -554.30% | -548.08% | -358.19% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -41.36% | -153.08% | 1,840.26% | 2,597.00% | 7,955.73% |
| Cash from Investing | -41.36% | -153.08% | 1,161.63% | 463.46% | 952.73% |
| Total Debt Issued | -- | -- | 32.77% | 17.84% | -- |
| Total Debt Repaid | 92.85% | 92.32% | -1,524.33% | -112.43% | -13.95% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 88.40% | 29.97% | -159.18% |
| Cash from Financing | 108.18% | 92.94% | 79.43% | 33.36% | 66.15% |
| Foreign Exchange rate Adjustments | -11.60% | -99.06% | -125.72% | -114.32% | 154.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -19.01% | -223.92% | 8.52% | 57.75% | 399.88% |